Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brittany O'Bryan

Urology Elizabethtown, KY Medical Doctor

NPI 1093159303 CMS profile 1392662

1700 Ring Rd, Elizabethtown, KY 42701

Open in the dashboard

General payments

$5,172

100 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany O'Bryan of Elizabethtown, KY is reported in the CMS Open Payments database as having received $5,172 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $479 17
2024 General $708 12
2023 General $3,181 30
2022 General $420 17
2021 General $19 1
2020 General $40 3
2019 General $325 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany O'Bryan
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Brittany O'Bryan were reported at $479. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Brittany O'Bryan Urology median Middle half National median
2019 $325 $480 $147–$1,201 $163
2020 $40 $246 $87–$645 $114
2021 $19 $358 $111–$1,000 $132
2022 $420 $476 $143–$1,263 $149
2023 $3,181 $560 $168–$1,461 $160
2024 $708 $563 $170–$1,464 $164
2025 $479 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,199 31 payments
  2. PROCEPT BioRobotics Corporation $693 5 payments
  3. C. R. Bard, Inc. & Subsidiaries $296 13 payments
  4. Medtronic USA, Inc. $226 13 payments
  5. Davol Inc. $113 3 payments
  6. Medtronic, Inc. $104 4 payments
  7. AbbVie, Inc. $100 6 payments
  8. Axonics Modulation Technologies, Inc. $71 4 payments
  9. Rochester Medical Corporation $50 2 payments
  10. Pfizer Inc. $50 3 payments
  11. Other $269 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,684 10 payments
  2. Food and Beverage $2,487 90 payments
Products named General payments · program years 2019–2025
  1. AMS 700 $1,383 14 payments
  2. TACTRA $699 3 payments
  3. AQUABEAM ROBOTIC SYSTEM $693 5 payments
  4. INTERSTIM Sacral Nerve Stimulation $226 13 payments
  5. Bard Urinary Drainage Bag $147 8 payments
  6. General - Therapies $111 2 payments
  7. INTERSTIM Sacral Nerve Stimulation $104 4 payments
  8. Phasix Mesh $95 2 payments
  9. Moses 550 D\F\L $63 1 payment
  10. Moses $57 1 payment
  11. Other $813 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,162

Median for Urology: 1,053

Drug cost

$83,401

Median for Urology: $101,464

Branded share of claims

30.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 50 $38,113
Gemtesa Vibegron Brand 23 $27,151
Solifenacin Succinate Generic 51 $4,308
Tamsulosin Hcl Generic 346 $3,372
Tolterodine Tartrate Er Tolterodine Tartrate Brand 37 $2,982
Estradiol Generic 40 $2,012
Oxybutynin Chloride Er Oxybutynin Chloride Brand 68 $1,993
Finasteride Generic 134 $1,320
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 68 $651
Oxybutynin Chloride Generic 109 $395

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$141,109

Medicare's payments for the services billed

Medicare patients

462

Average age 74

Services billed

1,892

154 women, 308 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 41%
Ischemic heart disease 36%
Chronic kidney disease 28%
Cancer 28%
COPD 25%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record